Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug
1. FDA requires confirmatory Phase 3 trial for apraglutide approval. 2. Ironwood engaged Goldman Sachs to explore strategic alternatives. 3. Strong efficacy data from STARS trial but lower than expected doses. 4. Completion of NDA submission expected by Q3 2025. 5. IRWD stock dropped 30.28% to 66 cents.